{"id":7437,"date":"2024-07-15T09:38:37","date_gmt":"2024-07-15T01:38:37","guid":{"rendered":"https:\/\/www.backvita.com\/?p=7437"},"modified":"2025-02-06T10:50:37","modified_gmt":"2025-02-06T02:50:37","slug":"ergothioneine-antioxidant","status":"publish","type":"post","link":"https:\/\/www.backvita.com\/ko\/ergothioneine-antioxidant\/","title":{"rendered":"\uc5d0\ub974\uace0\ud2f0\uc624\ub124\uc778, \ud56d\uc0b0\ud654\uc81c"},"content":{"rendered":"
\"\uc5d0\ub974\uace0\ud2f0\uc624\ub124\uc778\"<\/figure><\/div>\n\n\n\n

Ergothioneine: a powerful \ub178\ud654 \ubc29\uc9c0<\/a> agent found in nature<\/p>\n\n\n\n

In the dietary supplement industry, countless brands have launched single-ingredient products with superposition, bioavailability and purity. However, these products often do not live up to their claimed efficacy or are not supported by scientific testing. The same is true for the antioxidants on the market today, many of which claim to support the immune system. Ergothioneine is one of the oldest biologically active ingredients. Ergothione is not produced in the body, it must be obtained through the diet. Science has never been conclusive, but the leading hypothesis regarding the origin of ergothionein (EGT) is that it actually predates oxidation in the Earth\u2019s atmosphere, which, if true, would put its age at about 2.4 billion years. This would undoubtedly make ergothioneine (EGT) one of the oldest bioactive compounds known to science.<\/p>\n\n\n\n

Biosynthesis of ergothionein and its anti-aging mechanism<\/h2>\n\n\n\n

Given this, it\u2019s not surprising that human cells have shown a high affinity for ergothioneine (ET) \u2013 it\u2019s been with them basically throughout human evolution. It should come as no surprise that ergothioneine (EGT) plays an important supporting role in many aspects of human health.<\/p>\n\n\n\n

Ergothioneine (ET) is a naturally occurring antioxidant found in a variety of uncommon foods, especially edible mushrooms. [6,7] A large number of convincing studies have shown that ergothioneine (EGT) can provide profound protection against oxidative stress, improve immune and inflammatory function, and protect cells from many different types of cytotoxins, especially in the skin, and of course, the benefits to skin health are actually just the tip of the iceberg when it comes to MitoPrime applications. The presence of an evolutionarily conserved ergothione specific cell transporter speaks volumes about the importance of this molecule to human longevity.<\/p>\n\n\n\n

On March 6th, 2024, Professor Yukio Kato of Kanazawa University\u2019s School of Pharmacy in Japan wrote an article titled \u201cErgothioneine promotes longevity and healthy aging in male mice\u201d in the journal GeroScience. The study found that ergothioneine supplementation extended the lifespan of mice and promoted healthy aging. Studies have shown that the median and mean survival age of mice fed ergothioneine at a dose of 4-5 mg\/kg body weight per day increased by 16% and 21%, respectively. In addition, the study found that treatment with 10 mM concentration of ergothione significantly extended the lifespan of C. elegans and improved the non-aging period. The conclusions of the paper suggest that ergothioneine intake can inhibit the aging process in several organs, including the kidney, liver and brain, and improve age-related learning and memory impairment. Of particular note, ergothioneine intake also led to significant age-related declines in body weight, fat mass, and average and maximum exercise speed. The 2016 study was published in \u201cErgothionein Levels Decrease with Age and Incidence of Cognitive Decline in the Elderly Population,\u201d and the 2020 study includes two, \u201cErgothionein Reduces mortality and cardiovascular disease risk,\u201d and \u201cErgothionein is the\u201d longevity vitamin \u201cin the American Diet,\u201d published in the Journal of Nutritional Sciences. The 2022 study was published in the Journal of Food Function, titled \u201cErgothioneine shows life-prolonging effects in Drosophilia by regulating cholinergic neurotransmission, tyrosine metabolism, and fatty acid oxidation.\u201d The joint findings of this series of papers demonstrate that ergothioneine works through a super-antioxidant at the mitochondrial level of the cell.<\/p>\n\n\n\n

According to a 2020 article published in the Journal of Nutritional Sciences, the United States, a country with a high incidence of neurological diseases, has a lower intake of ergothioneine (EGT) compared to countries with similar levels of economic development. For example, Italians consume about 4.6 mg of ergothioneine (EGT) per day from food, while Americans consume only 1.1 mg. [10] Among the countries examined in this study, ergothioneine (EGT) intakes were highest in Italy and lowest in the United States, so 1.1 to 4.6 mg is a reasonable range for appropriate EGT intakes. In general, MitoPrime is taken at least 5 mg per day, however, since it is accumulated and, like creatine and beta-alanine, has a loading period, more \u201cloading\u201d doses can be strategically utilized to enhance the effect (e.g. 15-25 mg per day), especially if supplementation is needed immediately. A supplement strategy of 25 mg per day can be used.<\/p>\n\n\n\n

Full effect anti-inflammatory<\/h2>\n\n\n\n

For obvious reasons, immune function has been a hot topic in recent years. Since both acute and chronic infections can seriously reduce quality of life and prevent you from reaching your full life potential, supporting immune function is one of the key goals of nutritional supplementation. Fortunately for us, numerous in vitro and animal studies have shown that ergothioneine (EGT) has powerful anti-inflammatory effects that can help your body cope with infectious diseases. For example, one study conducted on muscle cells found that ergothioneine (EGT) significantly reduced the inflammatory response of muscle cells to the fatty acid palmitic acid. [17] Cells pretreated with ergothioneine (ET) before exposure to palmitic acid had a much higher survival rate and produced much less of the inflammatory cytokine interleukin-6 (IL-6) compared to control cells. [17] Of course, this is only in cell cultures-so what about the results in animal experiments? In one study, researchers randomly assigned mice to receive either ergothioneine (EGT) or a placebo for 15 days. At the end of the treatment period, they induced ischemia in the rats to see how ergothionein (EGT) affected tissue damage caused by inadequate blood supply. [18] In the hours after ischemia, they measured the levels of inflammatory molecules, such as cytokines, in the rats\u2019 blood and tissues. They also conducted histological studies of intestinal tissue from the rats. [18] The researchers found that the rats treated with EGT showed significantly fewer signs of inflammation than the control group, and that their intestinal tissue recovered better from ischemia. Summarizing these findings, we can say that the intestinal tissue structure of the ergothioneine (ET) group was better preserved than that of the control group. [18] The anaerobic (literally no oxygen) origin of ergothioneine (EGT) can help us understand this result \u2013 after all, cutting off the blood supply (ischemia) causes damage primarily by depriving cells of oxygen. Since ergothioneine (EGT) initially appears to help organisms cope with cellular stress in an oxygen-free environment, it is logical that it could help mitigate the damage caused by cellular hypoxia. In another study, the researchers induced an experimental model of ARDS, an inflammatory disease of lung tissue. ARDS is a hot topic today because it is often triggered by a cytokine storm of uncontrolled lung inflammation, which is often associated with severe SARS-CoV-2 infections. [19] Rats treated with ergothioneine showed significantly lower cytokine activity and lung tissue damage after ARDS. [19] Myeloperoxidase (MPO) is an enzyme that is largely responsible for tissue damage caused by inflammation. The ability of ergothioneine (EGT) to inhibit MPO is an important factor in its anti-inflammatory activity. [7]MPO is also associated with the function of neutrophils (a type of white blood cell), which is why high neutrophil counts are strongly associated with adverse consequences of SARS-CoV-2 infection. [20,21] Neutrophils produce a large number of inflammatory free radicals and reactive oxygen species (ROS) in the process of immune function.<\/p>\n\n\n\n

Neutrophils are also necessary for immunity, so we don\u2019t want to get rid of them, but we do need some way to clean up the reactive oxygen species they produce to prevent oxidative damage to the surrounding tissues. It turns out that\u2019s exactly how ergothioneine (EGT) works. It has been shown to mop up free radicals produced by MPO-containing neutrophils, and ergothione is even better at scavenging free radicals than powerful antioxidants such as glutathione and vitamin C. [7] This is one of the main mechanisms by which ergothioneine (EGT) is able to prevent the cytokine storm common in severe SARS-CoV-2.<\/p>\n\n\n\n

Can improve cardiometabolic, keep the heart healthy and long life<\/h2>\n\n\n\n

The inhibitory effect of ergothioneine (EGT) on MPO myeloperoxidase is an important point for its cardiovascular benefits. This is because MPO inhibitors have antithrombotic and anticoagulant effects. When bound to neutrophils, MPO plays a crucial role in the formation of the extracellular matrix around neutrophils. These fibrin-containing stroma are called neutrophil extracellular traps, or NETS, and can wreak havoc on the cardiovascular system by binding to red blood cells. Because of this binding effect of NET, MPO activity can form clots (blood clots). Aiaa [15]<\/p>\n\n\n\n

Promotes the growth and repair of neurons<\/h2>\n\n\n\n

Our study of the ergothionein (EGT) transporter discussed at the beginning of this article, known as OCTN1, found that it plays a key role in helping neurons grow and differentiate, [35] which is a key component of healing after brain injury. A 2021 mouse study concluded that ergothioneine (EGT) supplements actually upregulate neurogenesis, significantly improving rodents\u2019 performance on memory tests. [36]<\/p>\n\n\n\n

Serum ergothioneine (ET) and the risk of neurological diseases<\/h2>\n\n\n\n

As we have seen in cardiovascular disease, serum EGT levels appear to be inversely associated with the risk of neurological disease \u2013 lower levels of EGT have been found in patients with Parkinson\u2019s disease [25] and mild cognitive impairment. [26] Research suggests that ergothioneine (ET) may be critical for nervous system health \u2013 lower levels of ET have been observed in patients with severe and mild cognitive impairment. [25 to 28]<\/p>\n\n\n\n

Effect on skin care<\/h2>\n\n\n\n

The body stores ergothionein not only in the liver, kidneys, eyes, and bone marrow, but also in the skin! [37,38] In fact, there is an entire 2009 journal article entitled \u201cSkin Cells and Tissues are able to use L-ergothionein as a component of their antioxidant defense system\u201d that explains the incredible potential of ergothionein (EGT) for skin protection and repair. [38] In fact, the aforementioned OCTN1 ergothione transporter is highly expressed in the human epidermis [38] and is used to fight reactive oxygen species, prevent lipid damage in skin cells, and protect DNA, especially when exposed to UV light and oxidative stress. [41] 38 \u2013<\/p>\n\n\n\n

UV damage caused by UV can be avoided<\/h2>\n\n\n\n

One study even concluded that only nanomolar amounts provide the following benefits:<\/p>\n\n\n\n

\u201cErgothioneine at nanomolar concentrations is effective in improving skin damage caused by UVA and can be considered an ideal food supplement for skin protection and\/or preparation of skin care products.\u201d [41] In in vitro studies, ergothioneine began to accumulate in as little as one day, and in just nine days, ergothioneine (ET) levels increased by 600%! [42] The researchers of this study concluded: \u201cIn summary, we provide evidence that skin cells and tissues can absorb, accumulate, and utilize the powerful antioxidant L-ergothionein.\u201d This naturally occurring amino acid site EGT and its receptor\/transporter have been reported to have multiple protective effects as components of the skin\u2019s antioxidant defense system.\u201d [38]<\/p>\n\n\n\n

Mechanism: Better perception of skin damage and activation of protective effects<\/p>\n\n\n\n

To make a long story short, ergothioneine (EGT) can activate Nrf2, a leucine zipper protein that plays an important regulatory role in cells, specifically involved in antioxidant stress and cellular defense mechanisms, resulting in a protective effect. This produces multiple effects (especially in UVA-irradiated cells) and helps protect collagen and extracellular matrix from degradation by increasing cell viability. [40]<\/p>\n\n\n\n

Protects hyaluronic acid from degradation<\/h2>\n\n\n\n

Many of us who study skin and joint care protocols know about hyaluronic acid, a molecule found in soft tissues that helps cells retain water and stay hydrated. A recent study from 2021 showed that ergothionein can actually protect hyaluronic acid from degradation. [43] This is very useful for general skin care, and we believe MitoPrime\u00ae can be even more effective. Ergothione protects hyaluronic acid, which has an interesting ripple effect \u2013 it leads to better overall wound healing! [43] Usually we don\u2019t think about using supplements to speed up wound healing, but it\u2019s something worth knowing and keeping in mind.<\/p>\n\n\n\n

\ubc31\ube44\ud0c0<\/p>\n\n\n\n

\ucc38\uc870:<\/p>\n\n\n\n

Halliwell, Barry; \u201cThe antioxidant paradox\u201d; The Lancet; 355(9210):1179-80; April 1, 2000; https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10791396\/<\/p>\n\n\n\n

Halliwell, Barry; \u201cThe antioxidant paradox: less paradoxical now?\u201d British journal of clinical pharmacology; vol. 75,3: 637-44; 2013; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3575931\/<\/p>\n\n\n\n

Rehman, A, et al; \u201cThe effects of iron and vitamin C co-supplementation on oxidative damage to DNA in healthy volunteers\u201d; Biochemical and Biophysical Research Communications; 246(1):293-8; May 8, 1998; https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9600109<\/p>\n\n\n\n

Podmore, Ian D, et al; \u201cVitamin C exhibits pro-oxidant properties\u201d; Nature; 392, page 559; 1998; https:\/\/www.nature.com\/articles\/33308<\/p>\n\n\n\n

Ramirez-Martinez, Alejandra, et al. \u201cIntake Assessment of L-Ergothioneine in Some European Countries and in the United States.\u201d Human and Ecological Risk Assessment: An International Journal, vol. 22, no. 3, 23 Oct. 2015, pp. 667\u2013677, 10.1080\/10807039.2015.1104241; https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10807039.2015.1104241<\/p>\n\n\n\n

Asahi, Takashi et al. \u201cA mushroom-derived amino acid, ergothioneine, is a potential inhibitor of inflammation-related DNA halogenation.\u201d Bioscience, biotechnology, and biochemistry vol. 80,2 (2016): 313-7. doi:10.1080\/09168451.2015.1083396; https:\/\/academic.oup.com\/bbb\/article\/80\/2\/313\/5939193<\/p>\n\n\n\n

Stoffels, Christopher, et al; \u201cErgothioneine stands out from hercynine in the reaction with singlet oxygen: Resistance to glutathione and TRIS in the generation of specific products indicates high reactivity\u201d; Free Radical Biology and Medicine; Volume 113, Pages 385-394; December 2017; https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0891584917311553<\/p>\n\n\n\n

Julia Tschirka, Madlen Kreisor, Janina Betz and Dirk Gr\u00fcndemann; \u201cSubstrate Selectivity Check of the Ergothioneine Transporter\u201d; Drug Metabolism and Disposition; 46(6):779-785; June 2018; https:\/\/dmd.aspetjournals.org\/content\/46\/6\/779.long<\/p>\n\n\n\n

Beelman, Robert B et al. \u201cIs ergothioneine a \u2018longevity vitamin\u2019 limited in the American diet?.\u201d Journal of nutritional science vol. 9 e52. 11 Nov. 2020, doi:10.1017\/jns.2020.44; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7681161\/<\/p>\n\n\n\n

Ames, Bruce N. \u201cProlonging healthy aging: Longevity vitamins and proteins.\u201d Proceedings of the National Academy of Sciences of the United States of America vol. 115,43 (2018): 10836-10844. doi:10.1073\/pnas.1809045115; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6205492\/<\/p>\n\n\n\n

Paul, B D, and S H Snyder. \u201cThe Unusual Amino Acid L-Ergothioneine Is a Physiologic Cytoprotectant.\u201d Cell Death & Differentiation, vol. 17, no. 7, 13 Nov. 2009, pp. 1134\u20131140, doi:10.1038\/cdd.2009.163; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2885499\/<\/p>\n\n\n\n

University of Basel; \u201cThe vitamin ergothioneine\u2014an antioxidant for oxygen-free areas?\u201d; October 4, 2017; https:\/\/phys.org\/news\/2017-10-vitamin-ergothioneinean-antioxidant-oxygen-free-areas.html<\/p>\n\n\n\n

Gr\u00fcndemann, Dirk et al. \u201cDiscovery of the ergothioneine transporter.\u201d Proceedings of the National Academy of Sciences of the United States of America vol. 102,14 (2005): 5256-61. doi:10.1073\/pnas.0408624102; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/pmid\/15795384\/<\/p>\n\n\n\n

Cheah, Irwin K, and Barry Halliwell. \u201cCould Ergothioneine Aid in the Treatment of Coronavirus Patients?.\u201d Antioxidants (Basel, Switzerland) vol. 9,7 595. 7 Jul. 2020, doi:10.3390\/antiox9070595; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7402156\/<\/p>\n\n\n\n

Cheah, Irwin K et al. \u201cAdministration of Pure Ergothioneine to Healthy Human Subjects: Uptake, Metabolism, and Effects on Biomarkers of Oxidative Damage and Inflammation.\u201d Antioxidants & redox signaling vol. 26,5 (2017): 193-206. doi:10.1089\/ars.2016.6778; https:\/\/www.liebertpub.com\/doi\/10.1089\/ars.2016.6778<\/p>\n\n\n\n

Laurenza, Incoronata et al. \u201cModulation of palmitic acid-induced cell death by ergothioneine: evidence of an anti-inflammatory action.\u201d BioFactors (Oxford, England) vol. 33,4 (2008): 237-47. doi:10.1002\/biof.5520330401; https:\/\/iubmb.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/biof.5520330401<\/p>\n\n\n\n

Sakrak, Omer et al. \u201cErgothioneine modulates proinflammatory cytokines and heat shock protein 70 in mesenteric ischemia and reperfusion injury.\u201d The Journal of surgical research vol. 144,1 (2008): 36-42. doi:10.1016\/j.jss.2007.04.020; https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022-4804(07)00277-6<\/p>\n\n\n\n

Repine, John E, and Nancy D Elkins. \u201cEffect of ergothioneine on acute lung injury and inflammation in cytokine insufflated rats.\u201d Preventive medicine vol. 54 Suppl,Suppl (2012): S79-82. doi:10.1016\/j.ypmed.2011.12.006; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3355229\/<\/p>\n\n\n\n

Wang, Dawei et al. \u201cClinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.\u201d JAMA vol. 323,11 (2020): 1061-1069. doi:10.1001\/jama.2020.1585; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7308057\/<\/p>\n\n\n\n

Zuo, Yu et al. \u201cNeutrophil extracellular traps in COVID-19.\u201d JCI insight vol. 5,11 e138999. 4 Jun. 2020, doi:10.1172\/jci.insight.138999; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7308057\/<\/p>\n\n\n\n

Valachov\u00e1, Katar\u00edna et al. \u201cThe importance of ergothioneine synthesis in ancient time by organisms living in oxygen free atmosphere.\u201d Medical hypotheses vol. 123 (2019): 72-73. doi:10.1016\/j.mehy.2018.12.015; https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306-9877(18)31118-6<\/p>\n\n\n\n

Ruszczycky, Mark W, and Hung-Wen Liu. \u201cBiochemistry: The surprising history of an antioxidant.\u201d Nature vol. 551,7678 (2017): 37-38. doi:10.1038\/551037a; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5830134\/<\/p>\n\n\n\n

Fuchs, Tobias A et al. \u201cExtracellular DNA traps promote thrombosis.\u201d Proceedings of the National Academy of Sciences of the United States of America vol. 107,36 (2010): 15880-5. doi:10.1073\/pnas.1005743107; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2936604\/<\/p>\n\n\n\n

Hatano, Taku et al. \u201cIdentification of novel biomarkers for Parkinson\u2019s disease by metabolomic technologies.\u201d Journal of neurology, neurosurgery, and psychiatry vol. 87,3 (2016): 295-301. doi:10.1136\/jnnp-2014-309676; https:\/\/jnnp.bmj.com\/content\/87\/3\/295.long<\/p>\n\n\n\n

Cheah, Irwin K et al. \u201cErgothioneine levels in an elderly population decrease with age and incidence of cognitive decline; a risk factor for neurodegeneration?.\u201d Biochemical and biophysical research communications vol. 478,1 (2016): 162-167. doi:10.1016\/j.bbrc.2016.07.074; https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006-291X(16)31196-2<\/p>\n\n\n\n

Wu, Liu-Yun, et al. \u201cLow Plasma Ergothioneine Predicts Cognitive and Functional Decline in an Elderly Cohort Attending Memory Clinics.\u201d Antioxidants, vol. 11, no. 9, 30 Aug. 2022, p. 1717, doi:10.3390\/antiox11091717; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9495818\/<\/p>\n\n\n\n

Wu, Liu-Yun, et al. \u201cLow Plasma Ergothioneine Levels Are Associated with Neurodegeneration and Cerebrovascular Disease in Dementia.\u201d Free Radical Biology and Medicine, vol. 177, Dec. 2021, pp. 201\u2013211, doi:10.1016\/j.freeradbiomed.2021.10.019; https:\/\/pubmed.ncbi.nlm.nih.gov\/34673145\/<\/p>\n\n\n\n

Smith, Einar et al. \u201cErgothioneine is associated with reduced mortality and decreased risk of cardiovascular disease.\u201d Heart (British Cardiac Society) vol. 106,9 (2020): 691-697. doi:10.1136\/heartjnl-2019-315485; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/pmid\/31672783\/<\/p>\n\n\n\n

Ericson, Ulrika et al. \u201cA Health-Conscious Food Pattern Is Associated with Prediabetes and Gut Microbiota in the Malm\u00f6 Offspring Study.\u201d The Journal of nutrition vol. 150,4 (2020): 861-872. doi:10.1093\/jn\/nxz293; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7138670\/<\/p>\n\n\n\n

Cobley, James Nathan et al. \u201c13 reasons why the brain is susceptible to oxidative stress.\u201d Redox biology vol. 15 (2018): 490-503. doi:10.1016\/j.redox.2018.01.008; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5881419\/<\/p>\n\n\n\n

Yang, Nae-Cherng et al. \u201cErgothioneine protects against neuronal injury induced by \u03b2-amyloid in mice.\u201d Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association vol. 50,11 (2012): 3902-11. doi:10.1016\/j.fct.2012.08.021; https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278-6915(12)00585-6<\/p>\n\n\n\n

Moncaster, Juliet A et al. \u201cErgothioneine treatment protects neurons against N-methyl-D-aspartate excitotoxicity in an in vivo rat retinal model.\u201d Neuroscience letters vol. 328,1 (2002): 55-9. doi:10.1016\/s0304-3940(02)00427-5; https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394002004275<\/p>\n\n\n\n

\u200cSong, Tuzz-Ying et al. \u201cErgothioneine protects against neuronal injury induced by cisplatin both in vitro and in vivo.\u201d Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association vol. 48,12 (2010): 3492-9. doi:10.1016\/j.fct.2010.09.030; https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278-6915(10)00606-X<\/p>\n\n\n\n

Ishimoto, Takahiro et al. \u201cOrganic cation transporter-mediated ergothioneine uptake in mouse neural progenitor cells suppresses proliferation and promotes differentiation into neurons.\u201d PloS one vol. 9,2 e89434. 25 Feb. 2014, doi:10.1371\/journal.pone.0089434; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3934899\/<\/p>\n\n\n\n

Nakamichi, Noritaka et al. \u201cOral Administration of the Food-Derived Hydrophilic Antioxidant Ergothioneine Enhances Object Recognition Memory in Mice.\u201d Current molecular pharmacology vol. 14,2 (2021): 220-233. doi:10.2174\/1874467213666200212102710; https:\/\/www.eurekaselect.com\/179259\/article<\/p>\n\n\n\n

Cheah, Irwin K., and Barry Halliwell. \u201cErgothioneine; Antioxidant Potential, Physiological Function and Role in Disease.\u201d Biochimica et Biophysica Acta (BBA) \u2013 Molecular Basis of Disease, vol. 1822, no. 5, 1 May 2012, pp. 784\u2013793, doi:10.1016\/j.bbadis.2011.09.017; https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0925443911002201<\/p>\n\n\n\n

Markova, Nelli G., et al. \u201cSkin Cells and Tissue Are Capable of Using L-Ergothioneine as an Integral Component of Their Antioxidant Defense System.\u201d Free Radical Biology & Medicine, vol. 46, no. 8, 15 Apr. 2009, pp. 1168\u20131176, 10.1016\/j.freeradbiomed.2009.01.021; https:\/\/pubmed.ncbi.nlm.nih.gov\/19439218\/<\/p>\n\n\n\n

Bazela, Karolina, et al. \u201cL-Ergothioneine Protects Skin Cells against UV-Induced Damage\u2014a Preliminary Study.\u201d Cosmetics, vol. 1, no. 1, 20 Mar. 2014, pp. 51\u201360, 10.3390\/cosmetics1010051; https:\/\/www.mdpi.com\/2079-9284\/1\/1\/51<\/p>\n\n\n\n

Hseu, You-Cheng, et al. \u201cThe Antiaging Activity of Ergothioneine in UVA-Irradiated Human Dermal Fibroblasts via the Inhibition of the AP-1 Pathway and the Activation of Nrf2-Mediated Antioxidant Genes.\u201d Oxidative Medicine and Cellular Longevity, vol. 2020, 12 Feb. 2020, pp. 1\u201313, 10.1155\/2020\/2576823; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7038158\/<\/p>\n\n\n\n

Hseu, You-Cheng, et al. \u201cDermato-Protective Properties of Ergothioneine through Induction of Nrf2\/ARE-Mediated Antioxidant Genes in UVA-Irradiated Human Keratinocytes.\u201d Free Radical Biology and Medicine, vol. 86, Sept. 2015, pp. 102\u2013117, 10.1016\/j.freeradbiomed.2015.05.026; https:\/\/pubmed.ncbi.nlm.nih.gov\/26021820\/<\/p>\n\n\n\n

Schauss, Alexander G., et al. \u201cThe Effect of Ergothioneine on Clastogenic Potential and Mutagenic Activity.\u201d International Journal of Toxicology, vol. 30, no. 4, 19 July 2011, pp. 405\u2013409, 10.1177\/1091581811405856; https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/1091581811405856<\/p>\n\n\n\n

Valachova, Katarina, et al. \u201cImpact of Ergothioneine, Hercynine, and Histidine on Oxidative Degradation of Hyaluronan and Wound Healing.\u201d Polymers, vol. 13, no. 1, 29 Dec. 2020, p. 95, 10.3390\/polym13010095; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7795610\/<\/p>\n\n\n\n

Cheah, Irwin K, and Barry Halliwell. \u201cErgothioneine, recent developments.\u201d Redox biology vol. 42 (2021): 101868. doi:10.1016\/j.redox.2021.101868; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8113028\/<\/p>\n\n\n\n

Marone, Palma Ann et al. \u201cA Safety Evaluation of a Nature-Identical l-Ergothioneine in Sprague Dawley Rats.\u201d International journal of toxicology vol. 35,5 (2016): 568-83. doi:10.1177\/1091581816653375; https:\/\/journals.sagepub.com\/doi\/10.1177\/1091581816653375<\/p>\n\n\n\n

Turck, Dominique, et al. \u201cSafety of Synthetic L\u2010Ergothioneine (Ergoneine\u00ae) as a Novel Food pursuant to Regulation (EC) No 258\/97.\u201d EFSA Journal, vol. 14, no. 11, Nov. 2016, 10.2903\/j.efsa.2016.4629; https:\/\/efsa.onlinelibrary.wiley.com\/doi\/full\/10.2903\/j.efsa.2016.4629<\/p>\n\n\n\n

Blue California; \u201cGRAS Notification of Ergothioneine Food Usage Conditions for General Recognition of Safety.\u201d FDA.gov, 2017, http:\/\/www.fda.gov\/files\/food\/published\/GRAS-Notice-000734\u2013Ergothionine.pdf (archive)<\/p>\n\n\n\n

Adams, Michael A, Keefe, Dennis M (FDA); \u201cAgency Response Letter Re: GRAS Notice No. GRN 000734: Ergothioneine\u201d; United States Food and Drug Administration; https:\/\/www.fda.gov\/media\/113846\/download (archive)<\/p>\n